medigraphic.com
ISSN 3122-3893 (Electronic)
ISSN 2007-6800 (Print)

2026, Number S1

<< Back

Rev Mex Traspl 2026; 15 (S1)

Mexican consensus on the diagnosis and management of atypical hemolytic uremic syndrome (aHUS)

Gómez-Navarro B, Morales-Buenrostro LE, Alamilla-Sánchez ME, Álvarez-Rangel LE, Arteaga J, Aréchiga-Andrade M, Bahena-Carrera L, Mejía-Vilet JM, Navarro-Ramírez AC, Rojas-Montaño A, Romo-Vásquez JC, Soto-Abraham MV, Valdez-Ortiz R, Valle-Noriega LA, Reyes-Morales L

Language: Spanish
References: 28
Page: s10-24
PDF size: 931.15 Kb.


ABSTRACT

Introduction: atypical hemolytic uremic syndrome (aHUS) is a rare and potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is associated with dysregulation of the alternative complement pathway, frequently linked to pathogenic genetic variants. Objective: this expert consensus aims to provide practical, evidence-based clinical recommendations for the diagnosis and management of aHUS, adapted to real-world settings. It also seeks to expedite diagnosis, standardize care criteria, optimize therapeutic decision-making, and reduce clinical variability, particularly in resource-limited settings. Material and methods: a multidisciplinary panel developed 21 clinical recommendations using a modified nominal group technique, supported by a systematic literature review and structured discussion and voting rounds. The recommendations were classified according to the ACC/AHA system. Results: the consensus addresses aspects such as risk stratification according to complement variants, early initiation of C5 inhibitors, management in the kidney transplantation setting, treatment duration, and criteria for discontinuation or continuation. Conclusion: this consensus provides a structured, evidence-based framework to improve clinical outcomes and promote more equitable care for aHUS in Mexico, with potential applicability to other Latin American settings.


REFERENCES

  1. Campistol JM, Arias M, Ariceta G et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. Nefrologia. 2015; 35: 421-447. doi: 10.1016/j.nefro.2015.07.005.

  2. García RJ, Zamora AR, Perdomo M del RMV, Ochoa AB, Delgado CTC. Síndrome urémico hemolítico atípico. Reporte de caso y revisión de la bibliografía. Acta Pediatr Mex. 2018; 39: 250-255. doi: 10.18233/apm39no3pp250-2551609.

  3. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5: 1844-1859. doi: 10.2215/CJN.02210310.

  4. Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016; 31: 15-39. doi: 10.1007/s00467-015-3076-8.

  5. Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N Engl J Med. 2009; 361: 1676-1687. doi: 10.1056/NEJMra0902814.

  6. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017; 390: 681-96. doi: 10.1016/S0140-6736(17)30062-4.

  7. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013; 368: 2169-2181. doi: 10.1056/NEJMoa1208981.

  8. Agencia Española de Medicamentos y Productos Sanitarios. Informe de posicionamiento terapéutico de ravulizumab (Ultomiris) en el tratamiento del síndrome hemolítico urémico atípico (SHUa) [Internet]. Madrid: AEMPS; 2022. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2022/IPT_62-2022-Ultomiris-SHUa.pdf

  9. Jones D, Hunter J. Consensus methods for medical and health services research. BMJ. 1995; 311: 376-380. doi: 10.1136/bmj.311.7001.376.

  10. Potter M, Gordon S, Hamer P. The nominal group technique: a useful consensus methodology in physiotherapy research. N Z J Physiother. 2004; 32: 126-130.

  11. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016; 38: 655-662. doi: 10.1007/s11096-016-0257-x.

  12. American Heart Association. Applying class of recommendation and level of evidence to clinical strategies, interventions, treatments, or diagnostic testing in patient care [Internet]. Dallas (TX): AHA; 2024. Available in: https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/tables/applying-class-of-recommendation-and-level-of-evidence

  13. Goodship THJ, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) controversies conference. Kidney Int. 2017; 91: 539-551. doi: 10.1016/j.kint.2016.10.005.

  14. Feitz WJC, van de Kar NCAJ, Orth-Holler D, van den Heuvel LPJW, Licht C. The genetics of atypical hemolytic uremic syndrome. Med Genet. 2018; 30 (4): 400-409. doi: 10.1007/s11825-018-0216-0.

  15. Frémeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8: 554-562. doi: 10.2215/CJN.04760512.

  16. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010; 31: E1445-E1460. doi: 10.1002/humu.21256.

  17. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405-423. doi: 10.1038/gim.2015.30.

  18. Greenbaum LA, Fila M, Ardissino G et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016; 89: 701-711. doi: 10.1016/j.kint.2015.11.026.

  19. Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA. Blood. 2024; 143: 1112-1123. doi: 10.1182/blood.2022017654.

  20. Garnier A, Brochard K, Kwon T et al. Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial. J Am Soc Nephrol. 2023; 34: 1561-1573. doi: 10.1681/ASN.2023010098.

  21. Zafar A, Lim MY, Abou-Ismail MY. Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature. Thromb Res. 2023; 226: 94-102. doi: 10.1016/j.thromres.2023.07.014.

  22. Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol. 2020; 21: 245. doi: 10.1186/s12882-020-01867-0.

  23. Gupta M, Govindappagari S, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review. Obstet Gynecol. 2020; 135: 46-58. doi: 10.1097/AOG.0000000000003608.

  24. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1-150.

  25. Macia M, Alvaro F, Pintos G et al. A retrospective study of atypical hemolytic uremic syndrome in Spain: identifying risk factors associated with poor outcomes. Nephrol Dial Transplant. 2010; 25: 2959-2965. doi: 10.1093/ndt/gfq099.

  26. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012; 8: 643-657. doi: 10.1038/nrneph.2012.214.

  27. Licht C, Ardissino G, Ariceta G et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 2015; 16: 207. doi: 10.1186/s12882-015-0203-4.

  28. Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014; 64: 633-637. doi: 10.1053/j.ajkd.2014.01.434.




2020     |     www.medigraphic.com